EHAB Quote, Financials, Valuation and Earnings

CVS Health has a net margin of -17.82% compared to Enhabit's net margin of 1.88%. Enhabit's return on equity of -23.93% beat CVS Health's return on equity of 7%.

Enhabit has a consensus price target of $9.56, signalling downside risk potential of -6.98%. On the other hand CVS Health has an analysts' consensus of $79.17 which suggests that it could grow by 18.21%. Given that CVS Health has higher upside potential than Enhabit, analysts believe CVS Health is more attractive than Enhabit.

Enhabit has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CVS Health has a beta of 0.598, suggesting its less volatile than the S&P 500 by 40.158%.

Enhabit has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 3.97% to investors and pays a quarterly dividend of $0.67 per share. Enhabit pays -- of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Enhabit quarterly revenues are $258.2M, which are smaller than CVS Health quarterly revenues of $94.6B. Enhabit's net income of -$46M is lower than CVS Health's net income of $1.8B. Notably, Enhabit's price-to-earnings ratio is -- while CVS Health's PE ratio is 15.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit is 0.50x versus 0.22x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings has a net margin of -17.82% compared to Enhabit's net margin of 6.5%. Enhabit's return on equity of -23.93% beat IQVIA Holdings's return on equity of 20.79%.

Enhabit has a consensus price target of $9.56, signalling downside risk potential of -6.98%. On the other hand IQVIA Holdings has an analysts' consensus of $197.72 which suggests that it could grow by 32.71%. Given that IQVIA Holdings has higher upside potential than Enhabit, analysts believe IQVIA Holdings is more attractive than Enhabit.

Enhabit has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.344, suggesting its more volatile than the S&P 500 by 34.416%.

Enhabit has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enhabit pays -- of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend.

Enhabit quarterly revenues are $258.2M, which are smaller than IQVIA Holdings quarterly revenues of $3.8B. Enhabit's net income of -$46M is lower than IQVIA Holdings's net income of $249M. Notably, Enhabit's price-to-earnings ratio is -- while IQVIA Holdings's PE ratio is 20.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit is 0.50x versus 1.75x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.

The Joint has a net margin of -17.82% compared to Enhabit's net margin of 7.09%. Enhabit's return on equity of -23.93% beat The Joint's return on equity of -37.87%.

Enhabit has a consensus price target of $9.56, signalling downside risk potential of -6.98%. On the other hand The Joint has an analysts' consensus of $15.38 which suggests that it could grow by 53.9%. Given that The Joint has higher upside potential than Enhabit, analysts believe The Joint is more attractive than Enhabit.

Enhabit has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Joint has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.11%.

Enhabit has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Joint offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enhabit pays -- of its earnings as a dividend. The Joint pays out -- of its earnings as a dividend.

Enhabit quarterly revenues are $258.2M, which are larger than The Joint quarterly revenues of -$38.3M. Enhabit's net income of -$46M is lower than The Joint's net income of -$2.7M. Notably, Enhabit's price-to-earnings ratio is -- while The Joint's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit is 0.50x versus 2.92x for The Joint. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of -17.82% compared to Enhabit's net margin of -55.94%. Enhabit's return on equity of -23.93% beat SCWorx's return on equity of -80.46%.

Enhabit has a consensus price target of $9.56, signalling downside risk potential of -6.98%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that Enhabit has higher upside potential than SCWorx, analysts believe Enhabit is more attractive than SCWorx.

Enhabit has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SCWorx has a beta of 2.355, suggesting its more volatile than the S&P 500 by 135.489%.

Enhabit has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enhabit pays -- of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend.

Enhabit quarterly revenues are $258.2M, which are larger than SCWorx quarterly revenues of $759.7K. Enhabit's net income of -$46M is lower than SCWorx's net income of -$425K. Notably, Enhabit's price-to-earnings ratio is -- while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit is 0.50x versus 0.30x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.